Authors
Latest:
Community Clinics as Trial Sites—Bridging the Gap Between Healthcare and Clinical ResearchKeith Fern looks at how community clinics can be turned into research sites.
Latest:
Nine Pharma Lessons from the BattlefieldRick Lynch, the Army General who led the Iraqi ‘surge’ campaign, cites nine lessons that pharma leaders can apply in today’s come-from-behind struggle for market share.
Latest:
Withdrawal of EU Investigation of the Patent Box: Good News for UK InnovatorsThe European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.
Latest:
The End of Pharma Marketing— or a New Beginning?Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.
Latest:
Case Study: A Drug Launch into COVID HeadwindsLessons to launch by during a pandemic—or otherwise.
Latest:
Biosimilars: Finding the Right Path to DifferentiationHow will companies market similarity in a way that differentiates from the innovator? Customer experience may be the key.
Latest:
Philanthropy vs. Innovation - Current Vaccine Prices: Is There a Downside?Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.
Latest:
Pharma Boards in the Era of Hostile TakeoversWith hostile takeovers on the rise, Mike Straw argues that pharma boards have a huge role to play in managing the people issues.
Latest:
Prastera: A Drug Listing Submission Case StudyMark Gross offers a case study in using structured product labeling (SPL) to reduce time to market.
Latest:
Pharma's Love Affair with BuzzwordsHow pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality, by Lundbeck's Timothy White.
Latest:
Tomorrow’s Selling Strategies: Invest & TestA new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Latest:
Value-Based Planning Uncovers True Drivers of Cost Across Life Sciences OrganizationsExplicitly tying strategic planning to resource allocation boosts bottom-line productivity for pharma.
Latest:
Tomorrow’s Selling Strategies: Invest & TestA new PwC survey reveals a strong need to fully embrace alternative commercial methods-not in a blind frenzy but through careful evaluation of which new sales strategies have true innovative potential.
Latest:
Refuting R&D Tax Credit MythsWhy executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.
Latest:
Biosimilars in the US: Five Key Commercial ConsiderationsRohit Sood outlines five critical factors for companies entering this blossoming market.
Latest:
So What is Pharma’s Ideal Role in Social?Advertorial: Ashfield Commercial & Medical Services believes that Pharma can use social media to play an important role in educating the healthcare professional (HCP) and the patient
Latest:
Accelerated Change: Understanding the FDA’s Expedited PathwaysJamie Gault outlines the key differentiators between each of FDA's programs to facilitate and expedite drug development and review of new drugs.
Latest:
Patients, Physicians, and Payers… How Can Pharma Do it All?The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric - combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora
Latest:
Personalized Medicine at a CrossroadsPersonalized medicine has reached a crossroads where fundamental change is not only appealing but essential, write Klarissa Hoday, Francesca Boggio, and Aleksander Ruzicic.
Latest:
Patients' Role in Healthcare Decisions Will Transform Industry’s Model of CareDavid Logue sees the industry adapting to address medical needs and deliver treatments to patients in ways that afford greater personal empowerment.
Latest:
Pharm Exec’s 14th Annual Press Audit: The Opioid Crisis Takes Center StageThe opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. George P. Sillup and Stephen J. Porth report.
Latest:
Five Indispensable Lessons from SXSWJanelle Starr was surprised to find this month's SXSW speakers talk about failure. But their failures are enlightening, and essential to their ultimate success.
Latest:
Data is Now the Key to MarketingNeil Gleghorn, looks at the upsurge of technology and metric-driven marketing operations in the strictly regulated pharmaceutical industries.
Latest:
The Goods and Services Tax: A Bane or a Boon for Indian Pharma?Dr. Anuj Gupta explains the potential implications of the GST- or the goods and services tax - on Indian pharma.
Latest:
FDA Steps Up Foreign InspectionsNew legislation and changes in policy at FDA are leading to better control of the API supply chain.
Latest:
Industry Optimism Outweighs Personal Job SecurityAmid the environment of a gradual economic recovery and continued consolidation of bio/pharmaceutical companies, scientists, technicians, and professionals involved in drug development expressed a mix of muted optimism and stagnant employment options.
Latest:
New Funding and Approval Pathways Prove PopularCompared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines.
Latest:
In a Dynamic Healthcare Market, Only the Adaptive Survive“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is most responsive to change.” In today’s healthcare market, Darwin's words have never been more relevant, writes Brad Ansley.
